Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cardio Conversations: Abbott Aspires To Build 'Future Ready' CRM Devices

Executive Summary

In this special extra episode of Medtech Insight's podcast series on cardiovascular technology, editor Reed Miller talked to Vish Charan, the divisional vice president of product development in Abbott's cardiac rhythm management division.

Abbott aspires to be a leader in development of "future-ready" cardiac rhythm management (CRM) devices that do not need to be frequently replaced or explanted.

Late last year, Medtech Insight talked to Leonard Ganz, Abbott’s CRM business as its divisional vice president of medical affairs and chief medical officer, to talk about the company's development of leadless CRM devices, including Aveir VR, the only leadless pacemaker with unique mapping capabilities that can be easily retrieved as the patient's need for new therapies change.  (Also see "Exec Chat: Abbott Bets On Modular And Leadless Devices To Be The Future Of Cardiac Rhythm Management" - Medtech Insight, 10 Aug, 2022.)

To get the engineer's perspective on how Abbott is trying to keep up with Boston Scientific and Medtronic in this space, editor Reed Miller recently talked to Vish Charan, the vice president of product development in Abbott's CRM division.

Charan is all too familiar with the challenges of managing traditional cardiac leads, since he started his career as an engineer working on cardiac leads at St. Jude Medical; he joined Abbott as an operations leader when Abbott acquired St. Jude about six years ago.

He also talked about his role with the company, the future of transvenous devices, and the potential to reach more patients earlier in the progression of arrhythmia to save lives and costs. 

Use the player below to hear the whole interview.



Further Reading

For more information on leadless CRM technology discussed in this interview, check out these articles from Medtech Insight.

Minute Insight: Abbott Rolls Out Navitor Next-Gen TAVR System To Catch Up To Medtronic And Edwards

Medtronic’s Extravascular ICD Hits Targets In Trial; Will Soon Compete With Boston Scientific’s S-ICD

Exec Chat: Abbott Bets On Modular And Leadless Devices To Be The Future Of Cardiac Rhythm Management

Cardio Conversations: Abbott's Electrophysiology CMO Christopher Piorkowski On Cardiac Mapping, PFA, VT And More

Minute Insight: Abbott’s Aveir VR To Take On Medtronic’s Micra In US Leadless Pacemaker Market

Cardiovascular Catch-Up: Abbott Launches Trial Of Dual-Chamber Leadless Pacer; Cardialen Studies Low-Energy Arrhythmia Treatment; And More

Boston Scientific Advances First ‘Modular’ Cardiac Rhythm Management System


Further Listening

Our other podcasts are available on Apple PodcastsGoogle PodcastsSoundCloud and TuneIn - also now on Spotify Podcasts - and via smart speakers if one of these platforms has been set up as your default podcast provider.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts